A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma

BACKGROUND: CEA is expressed in >90% of pancreatic cancers (PC) and may be an appropriate immunotherapy target. CEA is poorly immunogenic due to immune tolerance; CAP1-6D, an altered peptide ligand can help bypass tolerance. We conducted a pilot randomized phase I trial in PC patients to determin...

Descripción completa

Detalles Bibliográficos
Autores principales: Geynisman, Daniel M, Zha, Yuanyuan, Kunnavakkam, Rangesh, Aklilu, Mebea, Catenacci, Daniel VT, Polite, Blase N, Rosenbaum, Cara, Namakydoust, Azadeh, Karrison, Theodore, Gajewski, Thomas F, Kindler, Hedy L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019890/
https://www.ncbi.nlm.nih.gov/pubmed/24829746
http://dx.doi.org/10.1186/2051-1426-1-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019890/
https://www.ncbi.nlm.nih.gov/pubmed/24829746
http://dx.doi.org/10.1186/2051-1426-1-8

Ejemplares similares